britishbiosimilars.co.uk
BBA - Resources
http://britishbiosimilars.co.uk/resources/nhs-england
Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. Sustainable Pricing, Procurement and Reimbursement. Switching patients to biosimilars. Increasing patient access and improving patient care. Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. To read the full report.
pharmaqmtraining.eu
Links | PharmaQMtraining.eu
http://www.pharmaqmtraining.eu//links.html
The Rules Governing Medicinal Products in the European Union. Scientific Guidelines for Human Medicinal Products. Medicines and Healthcare products Regulatory Agency. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Heads of Medicines Agencies. Names and addresses of all the EU Agencies. Association of the British Pharmaceutical Industry. British Generic Manufacturers Association. European Generic Medicines Association.
app.citizenspace.com
UK consultation on the User Requirement Specifications for the UK Medicines Verification System - Delib - Citizen Space
https://app.citizenspace.com/ukmvo/consultation-on-the-ukmvs-urs
Skip to Main Content. UK consultation on the User Requirement Specifications for the UK Medicines Verification System. Closed 13 Jul 2016. Opened 15 Jun 2016. The Falsified Medicines Directive and associated Delegated Regulation was introduced by the EU in October 2015. It introduces measures which aim to prevent the entry of falsified medicines into the legal pharmaceutical supply chain. Over the last 2 years, the organisations representing the pharmaceutical manufacturers and supply chain stakeholders ...
britishbiosimilars.co.uk
BBA - Resources
http://britishbiosimilars.co.uk/resources/ims-data
Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. Sustainable Pricing, Procurement and Reimbursement. Switching patients to biosimilars. Increasing patient access and improving patient care. Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. To read the full report.
britishbiosimilars.co.uk
BBA - Hot topics
http://britishbiosimilars.co.uk/hot-topics
Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. Sustainable Pricing, Procurement and Reimbursement. Switching patients to biosimilars. Increasing patient access and improving patient care. Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. At present, (as of May...
britishbiosimilars.co.uk
BBA - Hot topics
http://britishbiosimilars.co.uk/hot-topics/sustainable-pricing-procurement-and-reimbursement
Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. Sustainable Pricing, Procurement and Reimbursement. Switching patients to biosimilars. Increasing patient access and improving patient care. Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. At present, (as of May...
britishbiosimilars.co.uk
BBA - Resources
http://britishbiosimilars.co.uk/resources/professional-groups
Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. Sustainable Pricing, Procurement and Reimbursement. Switching patients to biosimilars. Increasing patient access and improving patient care. Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. To read the full report.
britishbiosimilars.co.uk
BBA - Hot topics
http://britishbiosimilars.co.uk/hot-topics/increasing-patient-access-and-improving-patient-care
Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. Sustainable Pricing, Procurement and Reimbursement. Switching patients to biosimilars. Increasing patient access and improving patient care. Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. At present, (as of May...
britishbiosimilars.co.uk
BBA - Resources
http://britishbiosimilars.co.uk/resources/mhra
Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. Sustainable Pricing, Procurement and Reimbursement. Switching patients to biosimilars. Increasing patient access and improving patient care. Treat complex and long term conditions. Regulated to the same standards of safety, quality and efficacy as originator medicines. Competition, cost reduction and innovation. To read the full report.
biovisionltd.co.uk
BioVision Ltd. - Link’s - Pharmaceutical Industry
http://biovisionltd.co.uk/links.htm
Below is a list of links to important websites relevant to pharmaceutical Industry:. Ndash; Medicines and Healthcare products Regulatory Agency. Raquo; European Medicines Agency. Raquo; EU Legislation. Raquo; NHS Choices. Your health, your choices. The Proprietary Association of Great Britain. Dispensing Doctors' Association Welcome. Raquo; DH home. Raquo; British Generics. Pharmaceutical Services Negotiating Committee. Incoterms 2010 by the International Chamber of Commerce(ICC).
SOCIAL ENGAGEMENT